Cyclerion Therapeutics’ merger with Korsana Biosciences has closed, transforming the company formerly traded as CYCN into a publicly traded, preclinical-stage biotechnology business focused on neurodegenerative diseases, beginning with Alzheimer’s disease. The combined company now operates as Korsana Biosciences and trades on the Nasdaq Capital Market under the ticker KRSA.
Legacy Cyclerion securityholders owned approximately 1.17% of the combined company immediately after the transaction on a fully diluted basis. Eligible holders of Cyclerion common stock and Series A preferred stock were also entitled to receive contingent value rights tied to specified legacy assets.
Updated September 16, 2026: This article has been revised to reflect the completed merger, ticker change, reverse stock split, final ownership allocation, financing close, and contingent value rights.
Cyclerion Becomes Korsana After Merger Closes
Korsana completed its merger with Cyclerion on September 8. The combined company adopted the Korsana Biosciences name, and its shares began trading on the Nasdaq Capital Market as KRSA on September 9.
Immediately before the merger closed, Cyclerion completed a one-for-seven reverse stock split. Each outstanding share of pre-merger Korsana common stock was then converted into approximately 0.2074 shares of the combined company, adjusted for the reverse split.
At closing, Korsana had 45,541,425 common shares issued and outstanding. The company’s closing 8-K also reported 55,051,271 shares assuming the full exercise of its pre-funded warrants and conversion of its Series B preferred stock.
That total consists of the issued common shares, 5,361,846 shares underlying pre-funded warrants, and 4,148,000 shares issuable upon conversion of Series B preferred stock. It excludes outstanding options and Parasa Warrants and is not a GAAP weighted-average diluted share count.
The completed transaction means CYCN no longer represents the standalone Cyclerion business described in the original version of this article. Historical CYCN prices require adjustment for the reverse split, which changed the number of outstanding shares and the quoted per-share price without itself creating additional economic value.
Older Cyclerion analyst targets are also not directly comparable with KRSA’s current price without accounting for the reverse split, new capitalization, different operating business, and changed development pipeline.
Investors assessing similar companies can find additional context in ABBO’s guide to the differences between biotech and pharmaceutical stocks.
What the Deal Means for Former CYCN Holders
Immediately after the merger and financing, legacy Cyclerion securityholders owned approximately 1.17% of the combined company’s capital stock on a fully diluted basis. Korsana securityholders, including securities purchased through the financing, owned approximately 98.83%.
Those are the final post-closing percentages. The July 24 definitive proxy statement/prospectus had estimated approximately 1.1% for Cyclerion securityholders and 98.9% for Korsana securityholders, while earlier deal materials had cited 1.5% and 98.5%.
The transaction left legacy Cyclerion holders with a small collective equity stake in the combined company, although that percentage does not capture all their potential economic value.
Eligible pre-merger holders of Cyclerion common stock and Series A preferred stock were also entitled to one non-transferable contingent value right for each share held at the record time immediately before the merger.
The CVRs provide a contractual right to a proportionate share of any net proceeds from specified legacy assets. Those assets consist of Cyclerion’s equity interests in Tisento Therapeutics Holdings and its rights under a June 2021 license agreement with Akebia Therapeutics.
Any payment depends on the company receiving qualifying proceeds after permitted deductions. The filing expressly warns that CVR holders may receive no payment. The CVRs do not represent an ownership interest in Korsana and carry no voting or dividend rights.
The 1.17% ownership figure is therefore not a share-price target or a measure of immediate investment loss. Individual outcomes depend on the number of KRSA shares held after the reverse split, KRSA’s subsequent market price, and any eventual CVR proceeds.
Korsana also completed a private placement immediately before the merger, raising approximately $380 million in gross proceeds through common stock and pre-funded warrants.
The unaudited pro-forma balance sheet showed approximately $473.5 million in cash and cash equivalents as of June 30 after giving effect to the financing and transaction adjustments. The company rounded that amount to approximately $475 million and expects it to fund operations into 2029.
That runway remains a management projection rather than a guaranteed funding period.
Korsana’s Bull Case and Principal Risks
The investment case rests largely on Korsana’s cash position and its lead Alzheimer’s program, KRSA-028. The company describes KRSA-028 as an investigational, next-generation shuttled antibody targeting amyloid beta.
KRSA-028 uses Korsana’s THETA platform. Management says the technology combines transferrin receptor and Fc engineering and is designed to improve brain delivery, safety, and convenience. Those potential benefits remain company claims and have not been established through human clinical results.
KRSA-028 remained preclinical as of publication. In its July 24 definitive proxy statement/prospectus, Korsana said it had not initiated, conducted, or completed any clinical trials. The company also had no products approved for commercial sale and had generated no product-sales revenue.
Korsana expects Phase 1 healthy-volunteer data in mid-2027. It anticipates interim proof-of-concept data evaluating amyloid plaque clearance in Alzheimer’s patients by the end of 2027 or during the first quarter of 2028. Both milestones remain forward-looking and could be delayed or produce unfavorable results.
Management expects the capital to support operations into 2029, including through multiple KRSA-028 clinical milestones, based on its current plans and assumptions. Participation from biotechnology-focused investors funded the transaction but does not establish KRSA-028’s safety, efficacy, or likelihood of regulatory approval.
The investment case is concentrated around an early-stage lead program. Clinical trials could be delayed, fail to demonstrate sufficient safety or effectiveness, or produce evidence that does not support further development. Even with substantial cash, an unfavorable clinical outcome could materially affect the value investors assign to Korsana’s pipeline.
Dilution also remains relevant. The 55,051,271-share count assumes exercise or conversion of specified securities but excludes outstanding options and Parasa Warrants. Investors calculating market capitalization or per-share values should therefore identify which capitalization measure they are using.
ABBO’s coverage of Capricor Therapeutics’ regulatory setback provides a separate example of how regulatory evidence can rapidly change the valuation of a development-stage biotechnology company.
For former CYCN investors, the central question is no longer whether the merger will close. It is whether Korsana can convert its funding and drug-delivery platform into persuasive human clinical data. Until those results emerge, KRSA remains a high-risk biotechnology investment exposed to clinical progress, spending, future financing, and development-timeline changes.
Methodology: ABBO News reviewed Korsana’s merger-closing 8-K filed September 11, July 24 definitive proxy statement/prospectus, September 11 and September 15 Schedule 13D filings, unaudited pro-forma financial statements, the CVR Agreement, and the September 8 merger-closing release. The final ownership allocation was checked against the closing 8-K; capitalization and pro-forma cash arithmetic were independently recalculated. Information was revalidated through September 16, 2026. The article intentionally excludes a live stock price and market capitalization because those figures require a separate timestamped market-data check.
